Centoxin
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
This paper examines the development and termination of nebacumab (Centoxin®), a human IgM monoclonal antibody (mAb) drug…
Meningococcal septic shock (MSS) has high mortality and morbidity rates. In addition to the traditional prompt antibiotics and…
ABSTRACT This note describes the binding specificities of four lipid A monoclonal antibodies (MAbs) including Centoxin (HA-1A…
Human IgM monoclonal antibody A6H4C5 was manufactured by Centocor (Malvern, PA) and used in clinical trials as HA-1A (Centoxin…
BACKGROUND
Antiendotoxin monoclonal antibodies are under investigation as adjunctive therapy for severe sepsis. One of these…
The cytokines interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF alpha) have been…
ObjectiveThe in vivo neutralizing activities of an anti-lipopolysaccharide (LPS) antibody HA-1A (Centoxin [Centocor, Malvern, PA…
IN THIS ISSUE of theArchives, The National Committee for the Evaluation of Centoxin1 reports data from a French national registry…
OBJECTIVE
Evaluation of HA-1A treatment in patients with the sepsis syndrome.
DESIGN
Descriptive.
SETTING
Department of…
SummaryMonoclonal antibodies have been shown to reduce morbidity and mortality in selected subsets of patients with Gram-negative…